{"id":"NCT02565186","sponsor":"Eli Lilly and Company","briefTitle":"An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine","officialTitle":"An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-07","primaryCompletion":"2019-08-20","completion":"2019-08-20","firstPosted":"2015-10-01","resultsPosted":"2020-08-25","lastUpdate":"2020-08-25"},"enrollment":2171,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Disorders"],"interventions":[{"type":"DRUG","name":"Lasmiditan","otherNames":["LY573144"]}],"arms":[{"label":"Lasmiditan 100mg","type":"EXPERIMENTAL"},{"label":"Lasmiditan 200mg","type":"EXPERIMENTAL"}],"summary":"This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-na√Øve subjects with migraine. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.","primaryOutcome":{"measure":"Number of Participants With at Least 1 Treatment Emergent Adverse Event","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Lasmiditan 100mg","deltaMin":447,"sd":null},{"arm":"Lasmiditan 200mg","deltaMin":545,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":196,"countries":["United States","Germany","United Kingdom"]},"refs":{"pmids":["37965170","34366152","33784930","33730977","32447545","32093628","31433669"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":991},"commonTop":["Dizziness","Somnolence","Paraesthesia","Fatigue","Nausea"]}}